Who Paid My Doc
Walter Boyle
Critical Care Medicine Mendocino, CA Medical Doctor
NPI 1093733727 CMS profile 1134782
44791 Baywood Dr, Mendocino, CA 95460
General payments
$835
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Walter Boyle of Mendocino, CA is reported in the CMS Open Payments database as having received $835 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 77th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $14 | 1 | |
| 2019 | General | $820 | 2 |
Beside peers
- Walter Boyle
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Walter Boyle were reported at $0. Among 445 Critical Care Medicine profiles paid that year, the median was $97 and the middle half received between $33 and $255.
Show as a table
| Year | Walter Boyle | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $820 | $103 | $29–$256 | $163 |
| 2020 | $0 | $60 | $22–$164 | $114 |
| 2021 | $0 | $115 | $30–$249 | $132 |
| 2022 | $14 | $97 | $27–$196 | $149 |
| 2023 | $0 | $104 | $31–$245 | $160 |
| 2024 | $0 | $93 | $28–$268 | $164 |
| 2025 | $0 | $97 | $33–$255 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
139
Drug cost
$5,507
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rosuvastatin Calcium | Generic | 14 | $4,039 | |
| Levothyroxine Sodium | Generic | 42 | $560 | |
| Omeprazole | Generic | 18 | $384 | |
| Amlodipine Besylate | Generic | 24 | $238 | |
| Benazepril Hcl | Generic | 12 | $114 | |
| Atorvastatin Calcium | Generic | 17 | $109 | |
| Simvastatin | Generic | 12 | $63 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in California
Vanessa Moll
Critical Care Medicine · Stanford, CA
Romain Pirracchio
Critical Care Medicine · San Francisco, CA
Roger Mecca
Critical Care Medicine · Stanford, CA
Anushirvan Minokadeh
Critical Care Medicine · San Diego, CA
Juliana Barr
Critical Care Medicine · Palo Alto, CA
Xiaodong Yang
Critical Care Medicine · West Hollywood, CA
Related records
Critical Care Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.